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Introduction
Cancer development and progression involve coordinate changes 
in both oncogene and tumor suppressor function (1, 2). Specific 
protein phosphatases, such as protein phosphatase 2A (PP2A), act 
as critical negative regulators of oncogenic signaling and are mod-
ulated by physiological and pathological mechanisms (3–5). PP2A 
is a serine/threonine phosphatase that controls many cellular 
functions, such as cell cycle, growth, metabolism, and apoptosis 
(6). The core enzyme of PP2A is composed of a complex between 
the scaffolding subunit (A) and the catalytic subunit (C). Both the 
A and C subunits have 2 possible isoforms, α and β, with Aα and Cα 
accounting for the majority of each subunit in most cells. The core 
enzyme associates with a variety of regulatory subunits (B) to form 
the heterotrimeric holoenzyme complex (7). There are multiple 
B subunit families (B, B′, B′′, B′′′), each consisting of several iso-
forms and splice variants, bringing about the diversity of the PP2A 
holoenzyme. Whereas the B subunits are specific to tissue and cell 
type/developmental stage, the A and C subunits are ubiquitously 
expressed (8–10). Posttranslational modifications modulate PP2A 
activity and B subunit interactions. Signaling via MAPK and PI3K/
AKT pathways is regulated, in part, by PP2A, which dephosphory-
lates and inactivates multiple protein kinases. As a tumor suppres-
sor gene, PP2A is genetically altered or functionally inactivated in 
many cancers (11–15), and activation of PP2A represents a promis-
ing strategy for therapeutic intervention (5).
Results
We investigated whether activation of PP2A in KRAS mutant lung 
cancer cells could be a viable treatment approach. We developed 
small-molecule activators of PP2A (SMAPs) by reengineering tri-
cyclic neuroleptics (16) (Supplemental Figure 1; supplemental 
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liver function (Supplemental Tables 1–3). Similar studies showed 
efficacy of SMAPs in xenograft models utilizing A549, H441, and 
H358 KRAS mutant cells (Supplemental Figure 6, A–L, Supple-
mental Figure 4B, and Supplemental Figure 5, C–E). Additionally, 
we examined a transgenic KRASLA2 murine model, which harbors 
oncogenic KRAS alleles that are activated by spontaneous recom-
bination (20), leading to the development of lung tumors that are 
phenotypically and histologically similar to those found in human 
non–small cell lung cancer (NSCLC). SMAP treatment in this mod-
el caused a significant decrease in tumor burden and induction 
of apoptosis (Figure 2, E–H). Treatment with SMAPs decreased 
p-ERK levels in tumor cells, as revealed by IHC (Figure 2I). We 
also utilized a KRAS mutant patient-derived xenograft (PDX) 
model and found that treatment with SMAPs induced growth inhi-
bition of the tumors (Figure 2J). SMAP treatment induced apop-
tosis (Figure 2, K and L) and decreased phosphorylation of ERK 
(Figure 2M). These results indicate that SMAPs are well tolerated, 
orally bioavailable, and active in both transgenic and xenograft 
mouse models of KRAS mutant lung cancer.
To assess whether the biological effect of SMAPs was through 
PP2A activation, we utilized SV40 small T antigen as a form of 
target validation. The small T antigen of SV40 is known to bind 
the PP2A A subunit at the B subunit binding domain and prevent 
holoenzyme assembly, altering PP2A activity (21–23). Expression 
of the small T antigen in lung cancer H358 cells conferred resis-
tance to SMAP treatment in the xenograft model (Figure 3, A–F) 
while having no impact on response to the PP2A-independent 
mechanism of MK2206/AZD6244 combination treatment. West-
ern blotting and IHC analyses showed that, while SMAPs reduced 
p-ERK levels in control tumors, tumors expressing the small T 
antigen had no significant change (Figure 3, C–F, and Supplemen-
tal Figure 4C). This indicated that SMAP-mediated growth inhibi-
tion was dependent on functional PP2A holoenzymes.
Next, to assess binding of SMAPs to PP2A, a tritiated version 
of SMAP was prepared. Using equilibrium dialysis, tritiated SMAP 
bound to the PP2A heterodimer (AC) but not to the related serine/
threonine phosphatase PP1 or lysozyme, used as negative control 
proteins (Figure 4A). Binding assays were performed using puri-
fied recombinant A (PP2A A) and C (PP2A C) subunits, the AC 
dimer (PP2A AC), and the PP2A trimer (PP2A AB56C). The tritiat-
ed SMAP compound specifically bound the PP2A A subunit alone 
as well as the PP2A dimer and trimer that both contained the A 
material available online with this article; https://doi.org/10.1172/
JCI89548DS1). Tricyclic neuroleptics have been reported to acti-
vate PP2A, (17, 18) and this was proposed to be through direct 
binding of the PP2A Aα subunit. However, clinical trials evaluating 
these molecules in the early 1990s were restricted by dose-limiting 
CNS-related toxicity (19). Developing tricyclic neuroleptics as anti-
cancer agents required neutralization of their potent CNS pharma-
cology and improvement of their antiproliferative properties. By 
replacing the basic amine with a neutral polar functional group, the 
CNS effects were abrogated, and further chemical derivatization 
improved the anticancer potency of these SMAPs (17).
To determine the efficacy of our compounds, KRAS mutant 
lung cancer cell lines (A549, H441, H358, H23, and CALU-1) were 
treated with SMAPs. These SMAPs decreased cell survival and 
induced cell death in each of these cell lines (Figure 1, A–C, Sup-
plemental Figure 2, A–C and Supplemental Figure 3, A–C). SMAP 
treatment induced a significant increase in annexin V staining, 
which was prevented by cotreatment with the caspase inhibitor 
Z-VAD, indicating that cell death was through a caspase-depen-
dent mechanism (Supplemental Figure 2B and Supplemental 
Figure 3B). Additionally, treatment of these cell lines with SMAPs 
resulted in increased poly (ADP-ribose) polymerase (PARP) cleav-
age and decreased phosphorylation of ERK (Figure 1C, Supple-
mental Figure 2D, and Supplemental Figure 3D).
To evaluate the efficacy of SMAPs in vivo, we used xenograft 
and transgenic mouse models of KRAS-activated lung adenocarci-
noma. In the H358 xenograft model, SMAP treatment resulted in 
significant inhibition of tumor growth (Figure 2A) and the induc-
tion of apoptosis (Figure 2, B and C). Western blotting and IHC 
analyses showed substantial reductions of phosphorylated ERK 
(p-ERK) in the tumors (Figure 2, B–D, and Supplemental Figure 
4A). Single-agent SMAP treatment displayed efficacy similar to 
that of combination treatment with the kinase inhibitors MK2206 
(AKT inhibitor) plus AZD6244 (MEK inhibitor). This suggest-
ed that SMAP treatment simultaneously reduced signaling via 
multiple kinases. Importantly, there were no deaths, behavioral 
abnormalities, or changes in body weight during the course of 
treatments, indicating a favorable toxicity profile in these mod-
el systems (Supplemental Figure 5A). Additional evaluation of 
SMAPs administered at relatively high doses for 7 days showed no 
apparent adverse effects, and SMAP dosing resulted in no changes 
in clinical chemistry parameters, reflecting no apparent impact on 
Figure 1. SMAPs decrease cell viability and inhibit MAPK signaling. (A) Clonogenic assay of KRAS mutant cell lines (A549, H441, H358) treated with 
SMAPs for 3 weeks. (B) MTT assay in A549, H441, and H358 cells treated with increasing doses of SMAP at 24 hours. (C) Western blots for p-ERK and ERK 
normalized to GAPDH in KRAS mutant cell lines treated with SMAP. Data represent mean ± SEM from 3 experiments. *P < 0.05; **P < 0.01; ***P < 0.001, 
Student’s t test.
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cell culture or tumors in vivo required substantially higher concen-
trations of SMAP than those needed to saturate purified PP2A. We 
attribute this difference to nonspecific binding of SMAPs to albu-
min and possibly other proteins that reduce the effective free drug 
concentration available for binding to the target.
Photoaffinity labeling (PAL) was used to characterize bio-
chemical binding for the SMAP family of activators to the PP2A 
subunit, but did not bind to the PP2A C subunit (Figure 4B). We 
concluded that SMAPs bind the A subunit of PP2A. The KD using 
the PP2A A subunit was 235 nM (Figure 4C), and the half-maximal 
binding using the A subunit was at approximately 500 nM (Supple-
mental Figure 7A). Competition of different SMAPs with tritiated 
SMAP showed that they all could outcompete the interaction with 
the PP2A A subunit (Supplemental Figure 7B). Experiments with 
Figure 2. SMAPs promote tumor growth inhibition and inhibit MAPK signaling in KRAS mutant lung cancer. (A) 1 × 107 H358 cells were subcutaneously 
injected into nude mice and allowed to grow to an average of 100 mm3. Mice were treated with vehicle control (n = 10), a combination of 6 mg/kg MK2206 
and 24 mg/kg AZD6244 (n = 10), or 5 mg/kg SMAP (n = 10) twice a day for 4 weeks. Tumor volume over course of treatment is shown. (B) Tumors were 
evaluated by sacrificing the mice 2 hours after final treatment. Representative TUNEL staining and p-ERK staining of treated tumors. Scale bars: 20 μM. 
Original magnification: ×40. (C) Quantification of TUNEL positivity. (D) Quantification of p-ERK levels in xenograft tumors as performed by immunoblot-
ting and densitometry. (E) KRASLA2 mice were randomized into treatment groups after reaching 16 weeks of age. Mice were treated with vehicle control  
(n = 3) or 15 mg/kg SMAP (n = 3) orally twice a day for 3 weeks. Mice were sacrificed and lungs were extracted 2 hours after final treatment. Representative 
images of lungs. Scale bar: 5 mM. (F) Percentage of tumor volume was evaluated by ImageJ using 3 sections of H&E for each mouse. (G) Representative 
TUNEL staining. Scale bars: 50 μM. (H) Quantification of TUNEL positivity in all tumors treated. (I) Immunohistochemistry of p-ERK in treated animals. 
Scale bars: 20 μM. Original magnification: ×40. (J) KRAS mutant PDX tumor fragments were surgically reimplanted in the right flank of NSG mice. Mice 
were treated with vehicle control (n = 7) and 5 mg/kg SMAP (n = 6) twice a day for 4 weeks. Tumor volume over course of treatment. (K) Tumors were 
evaluated by sacrificing mice 2 hours after final treatment. Representative TUNEL staining. Scale bar: 20 μM. Original magnification: ×40. (L) Quantifica-
tion of TUNEL positivity in all tumors treated. (M) Immunohistochemistry of p-ERK in treated animals. Scale bar: 20 μM. Original magnification: ×40. Data 
represent mean ± SEM. *P < 0.05; **P< 0.01; ***P < 0.001, Student’s t test.
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the exception of a single peptide, 184-AAASKLGEFAKVLELD-
NVK-202 of the A subunit (within the HEAT domain 5–8), which 
had a mass increase of 439.11 Da only in the +drug/+UV sam-
ples for each independently completed experiment. This mass 
increase matches the predicted mass of the nitrene DT-453 
adduct to this peptide within 3 ppm.
Based on the PAL experiments, we tentatively assigned 
drug binding to the flexible HEAT repeat domains 5–8 in the 
PP2A A subunit. To more precisely characterize the binding 
site and to explore drug-induced conformational changes in 
PP2A, we conducted hydroxyl radical footprinting (HRF) and 
MS experiments to characterize the SMAPs binding to the 
core enzyme (PP2A AC) using DT-453, a well-characterized 
SMAP analog. For the PAL experiments, a photoactivatable 
nitrene was incorporated in DT-453 such that covalent attach-
ment between drug and protein was generated upon treatment 
with UV and activation of the nitrene (Supplemental Figure 8 
and Supplemental Figure 9, A and B). The samples, which includ-
ed a PP2A AC experimental sample (+ drug/+UV), PP2A AC (+ 
drug/–UV) nonactivated control, and PP2A AC (–drug/–UV) 
negative control, were digested using trypsin and analyzed by 
liquid chromatography–mass spectrometry (LC-MS). Compari-
son of the MS and MS/MS spectra of the sets of tryptic peptides 
identified a common set of unmodified tryptic peptides, with 
Figure 3. Expression of the small T antigen confers resistance to SMAPs. (A and B) 1 × 107 H358 control (A) and H358 small T antigen (ST) (B) cells were subcuta-
neously injected into nude mice and allowed to grow to an average of 100 mm3. Mice were treated with vehicle control (n = 9 for H358 control; n = 8 for H358 ST), a 
combination of 6 mg/kg MK2206 and 24 mg/kg AZD6244 (n = 8 for H358 control;n = 7 for H358 ST), and 5 mg/kg SMAP (n = 9 for H358 control; n = 7 for H358 ST) 
twice a day for 4 weeks. Tumor volume over course of treatment. (C) Representative TUNEL staining of treated tumors and immunohistochemistry of SV40  
T antigen and p-ERK in treated animals. Scale bars: 20 μM. Original magnification: ×40. (D) Quantification of TUNEL positivity. (E) Quantification of SV40 T anti-
gen levels. (F) Quantification of p-ERK levels. Quantification of SV40 T antigen and p-ERK levels in the xenograft tumors was performed by immunoblotting and 
densitometry. TUNEL, anti-SV40 T, and ERK signaling in the tumors were evaluated by sacrificing the mice 2 hours after final treatment. Data represent mean ± 
SEM. *P < 0.05; **P < 0.01; ***P < 0.001, Student’s t test.
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side the putative drug-binding region. Assays of PP2A with a 
peptide substrate showed a dose-dependent increase in phos-
phatase activity of AC and AB56C with added SMAP (Supple-
mental Figure 10, A–D). Thus, the conformational changes due 
to SMAP binding produce activation of the phosphatase.
Based on the HRF results, the 194–198 region of the A subunit 
was identified as a putative SMAP-binding region, and K194, E197, 
and L198 were identified as potential sites of interaction. There-
fore, mutations of residues K194, E197, and L198 were created 
using site-directed mutagenesis of a pLX304 vector containing a 
V5-tagged PP2A Aα (Supplemental Figure 11, A–F). H358 cells sta-
bly overexpressing WT or the mutated PP2A A subunit were com-
pared with cells with pLX304 EGFP as controls. Tumor xenografts 
in mice using these cell lines, including both EGFP and WT PP2A 
as controls, were treated with SMAP (Figure 5, A–H, and Supple-
mental Figure 12, A–L). Tumors with mutations K194R and L198V 
at the putative drug-binding site in PP2A Aα exhibited resistance 
to SMAP treatment (Figure 5, E–G, and Supplemental Figure 12, 
I–K). Treatment response with combination AKT inhibitor and 
MEK inhibitor (MK2206/AZD6244) was not affected by expres-
sion of these mutations, supporting once again a PP2A-dependent 
mechanism of action for these SMAPs. Western blotting and IHC 
analyses showed that, while the tumors expressing control EGFP 
and WT PP2A had reductions of p-ERK, tumors expressing the 
mutations K194R and L198V did not show significant changes in 
these markers when treated with SMAPs (Figure 5, B, D, F, and H; 
Supplemental Figure 12, B, D, F, H, J, L; and Supplemental Figure 
13, A–E). Additionally, coimmunoprecipitation analyses and PP2A 
activity assays showed that the mutant Aα proteins were compe-
tent to form holoenzymes that were as active as AC with the WT A 
subunit (Supplemental Figure 11, A–F). Together, these data indi-
cate that SMAP-mediated growth inhibition was dependent on 
PP2A activation and that residues K194 and L198 in the A subunit 
are required for SMAP activity.
scaffolding subunit of PP2A (24, 25). Hydroxyl radicals (▪OH) 
generated during exposure to x-rays oxidatively modify solvent 
accessible amino acid side chains and provide high resolution 
information on solvent accessibility based on the observed 
extent of modification, which can be quantified at the peptide 
and side-chain level. Drug-binding sites and ligand-induced 
conformational changes were visualized using existing 3D pro-
tein structure information. We performed HRF on the PP2A AC 
complex in the absence and presence of various SMAPs, includ-
ing SMAP, SMAP2, and SMAP3, which have varying efficacy in 
cancer suppression. Samples of each protein in solution were 
exposed to x-rays, followed by digestion with both pepsin and 
trypsin enzymes, and subsequent analysis by LC-MS to deter-
mine extents and rates of modification and MS/MS to deter-
mine the sites of modification. A protection factor (PF) for each 
specific side chain was calculated as the ratio of modification 
rate for PP2A AC divided by the modification rate for the PP2A 
AC-SMAP complex (Supplemental Table 4). PFs greater than 
1 represent drug-dependent reduction in the hydroxyl radical 
labeling of PP2A AC due to direct binding of the drug to the pro-
tein and/or conformational changes induced within the com-
plex upon SMAP binding. In particular, for SMAP binding, the 
observed PF values ranged from 0.9 to 38.5, with median values 
of 5.4 for the A subunit. Residues K194, E197, and L198 within 
the peptic peptide 192-KAVLEL-198 of the A subunit exhibited 
large PFs of 18, 23, and 18, respectively. These sites are high-
lighted in Figure 4D and are contained on the outer connect-
ing loop of HEAT repeats 5 and 6. These results, complement-
ed by the equilibrium dialysis, PAL, and molecular modeling, 
suggest the high PF values for residues K194, E197, and L198 
in the A subunit are due to SMAP binding the A subunit within 
the 194–198 region (Figure 4D). The HRF data suggest a model 
indicating that SMAP binding to the PP2A A subunit promotes 
conformational changes, supported by the high PF values out-
Figure 4. SMAPs binding to protein phosphatase PP2A. (A) Binding studies of radiolabeled SMAPs with PP2A AC dimer, lysozyme, and PP1 using equi-
librium dialysis. (B) Binding of radiolabeled SMAPs to lysozyme as negative control and PP2A (A–C) subunits using equilibrium dialysis. (C) Quantification 
of the KD and binding maximum (Bmax) for SMAP against the PP2A trimer. Data represent mean ± SD of 3 experiments. (D) Projection of changes in solvent 
exposure based on hydroxylradical modification in the A subunit of PP2A AC upon SMAP ligand addition. The structure of the A subunit (in light gray) is 
taken from 2A (PP2A) holoenzyme (PDB 2IAE). Modified amino acids are represented by colored side chains. The color codes indicate the changes in rates 
of modification for each specific site upon SMAP binding to the A subunit of PP2A AC. Purple indicates the residues that showed change in modification 
of less than 0.5-fold, blue indicates the residues that show minimal to no change (< 2-fold) in modification, green indicates decreases of more than 2-fold 
and less than 4-fold, yellow indicates decreases of more than 4-fold and less than 6-fold, orange indicates decreases of more than 6-fold and less than 
9-fold, and red indicates decreases of more than 9-fold in the modification rate upon SMAP binding. Data represent mean ± SEM.
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Discussion
The studies presented here demonstrate that small molecules 
derived from the tricyclic neuroleptics phenothiazine and 
dibenzazepine directly activate PP2A in KRAS mutant lung 
cancer and thereby inhibit tumor growth and induce apoptosis. 
KRAS signaling is altered in about 20% of human cancers (26, 
27). Small-molecule inhibitors that target protein kinases in the 
RAS pathway have been developed and are FDA approved (1). 
However, potential resistance to inhibition of KRAS signaling 
can involve mutations in targets or activation of compensatory 
mechanisms (28–30). Inhibiting multiple pathways concurrent-
ly with the MEK and AKT inhibitors, AZD6244 and MK2206, 
respectively, successfully abrogates tumor growth in preclinical 
models (31). While kinase inhibitor combination therapy is a 
promising option, the limitation lies in determining the appro-
priate window with maximal activity and lowest toxicity. PP2A 
activation by SMAPs simultaneously inhibits multiple oncogen-
ic signaling pathways by inactivation of kinases that are sub-
strates of the phosphatase. Therapeutic activation of a protein 
phosphatase such as PP2A is a newly emerging tactic, which 
concurrently indirectly targets several oncogenes with a single 
agent. We included a combination of the kinase inhibitors arm 
in our preclinical in vivo studies and demonstrated a compara-
ble activity of SMAPs to the “double-down double-win” effect 
of combination therapies described by Shimizu et al. (32). These 
results underscore the advantage of targeting phosphatases 
such as PP2A with tumor-suppressive potential.
Several lines of evidence support the tumor-suppres-
sor role of PP2A: (a) PP2A is mutated and inactive in several 
human cancers; (b) overexpression of the endogenous inhibi-
tory proteins of PP2A, namely CIP2A and SET, is observed in 
tumors; and (c) inhibition of PP2A by small T polyoma virus 
SV40 and okadaic acid promotes cellular transformation and 
tumor growth in mice, respectively (13, 33–37). The restoration 
of PP2A activity has been explored as a therapeutic strategy in 
the context of pancreatic cancer and acute myeloid leukemia. 
Fingolimod FTY720 and its chiral deoxy analog drugs were 
used to indirectly reactivate PP2A by partly blocking the PP2A 
inhibitor protein SET (38). However, direct activation of the 
tumor-suppressor PP2A is observed with phenothiazines that 
Figure 5. Effects of mutations in putative drug-binding site. (A) Male nude mice were subcutaneously injected (1 × 107 cells per injection) in the right flank 
with the different isogenic cell lines (control EGFP and putative drug-binding mutant K194R). Once the tumors reached a volume of 100 mm3, the mice 
were randomly enrolled in vehicle control (n = 6 for EGFP; n = 9 for K194R), a combination of 6 mg/kg MK2206 and 24 mg/kg AZD6244 (n = 8 for EGFP; n = 7 
for K194R), or 5 mg/kg SMAP (n = 7 for EGFP; n = 9 for K194R) twice a day for 4 weeks. Mouse tumor volume for control EGFP-expressing H358 xenograft 
over course of treatment. (B) Tumors were evaluated by sacrificing the mice 2 hours after final treatment. Representative TUNEL staining and p-ERK IHC 
of treated tumors. Scale bars: 20 μM. Original magnification: ×40. (C) Quantification of TUNEL positivity in tumor. (D) Quantification of p-ERK levels in the 
xenograft tumors as performed by immunoblotting and densitometry. (E) Mouse tumor volume for drug-binding mutant K194R expressing H358 xeno-
graft over course of treatment. Tumor volume over course of treatment. (F) Tumors were evaluated by sacrificing the mice 2 hours after final treatment. 
Representative TUNEL staining and p-ERK IHC of treated tumors. Scale bar: 20 μM. Original magnification: ×40. (G) Quantification of TUNEL positivity in 
tumors treated. (H) Quantification of p-ERK levels in xenograft tumors as performed by immunoblotting and densitometry. Data represent mean ± SEM. 
*P < 0.05; **P < 0.01; ***P < 0.001, Student’s t test.
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directly bind the scaffold PP2A Aα subunit (16). Therefore, 
we generated a series of SMAPs by decoupling the CNS phar-
macology from the antiproliferative properties of phenothi-
azines. The derivatives with enhanced antiproliferative effect 
as well as in vivo bioavailability were used in the experiments 
described in this study. Activation of PP2A via the SMAPs in 
KRAS-driven lung adenocarcinoma mouse xenografts or PDX 
models and the transgenic KRASLA2 murine model resulted 
in substantial  tumor-growth inhibition compared with vehi-
cle control. Furthermore, mutation of residues at the putative 
drug-binding site completely abrogated the antitumorigenic 
effect of SMAP. These results were predicted by in vitro assays 
showing that SMAP binds directly to the scaffolding A subunit 
of PP2A. Aside from the phenothiazines themselves that harbor 
pharmacological toxicities, our SMAPs are the first generation 
of anticancer molecules, to our knowledge, that directly bind 
and activate a tumor-suppressor enzyme. Based on changes 
seen in the solvent exposure of the PP2A A subunit upon ligand 
binding, we propose that SMAPs act by inducing conformation-
al changes in the A subunit of PP2A. This is further supported 
by evidence that the SV40 small T antigen abrogates SMAP 
activity. The small T antigen acts on PP2A by replacing the B 
subunits; therefore, the ability of small T to abrogate SMAP 
activity supports the notion that regulatory subunit function 
in the ABC holoenzymes is essential for SMAP activity (21–23). 
These findings may extend to other malignancies driven by 
oncogenic substrates of PP2A or malignancies characterized 
by PP2A inactivation due to the overexpression of endogenous 
inhibitors. Additional development and the combination of 
SMAPs with other targeted therapies will enable the translation 
of our findings to patients. Finally, our results and approaches 
could provide the structural and molecular framework for the 
pharmacological reactivation of other phosphatases.
Methods
Cell lines and reagents. Human lung cancer cell lines were purchased 
from ATCC. All cells were cultured in RPMI supplemented with 5% 
FBS and 1% penicillin/streptomycin. The cells were treated with the 
SMAPs (dissolved in DMSO) and screened for cell viability through 
the MTT assay using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide kit (Sigma-Aldrich). The CyQUANT Cell Prolifera-
tion Kit was purchased from Thermo Fisher Scientific. MK2206 (AKT 
inhibitor) and AZD6244 (MEK inhibitor) were purchased from Sell-
eck. These compounds were diluted in DMSO and stored at –20°C. All 
SMAP compounds were diluted with DMSO and stored at room tem-
perature. Cells were treated with 20 μM of SMAPs in all assays unless 
otherwise stated. PPP2R1A (Homo sapiens) in pLX304 (Gateway V5–
tagged lentiviral expression vector) was purchased from the DNASU 
Plasmid Repository (no. HsCD00444402). Pbabe-small T retroviral 
plasmid was purchased from Addgene (Addgene plasmid 10673). 
H358–small T cell line was generated following the Gryphon retroviral 
expression protocol.
Antibodies. For immunoblotting, antibodies specific for p-ERK 
(no. 9272), ERK (no. 4695), PP2A A (no. 2041S), PP2A C (no. 2038), 
V5-tag (no. 13202S), and vinculin (no. 13901S) were obtained from 
Cell Signaling Technology. PARP p85 fragment (no. G7341) was 
purchased from Promega. GAPDH antibody (no. sc-32233) was pur-
chased from Santa Cruz Biotechnology Inc. SV40 small T antigen anti-
bodies (pab280) were purchased from EMD Millipore. For immuno-
histochemistry, p-ERK antibody (Thr202/Tyr204) XP (no. 4370) was 
obtained from Cell Signaling Technology.
Western blotting. Protein was isolated from cells with RIPA Lysis 
and Extraction Buffer (Thermo Fisher Scientific) and from animal tis-
sues with T-PER Tissue Protein Extraction Reagent (no. 78510, Ther-
mo Fisher Scientific) with complete ULTRA Tablets (no. 05892791001, 
Roche). Isolated protein was quantified and normalized via Bio-Rad 
assay. Protein was run on 12% SDS–polyacrylamide gel electrophore-
sis gels (Invitrogen, Life Technologies) and transferred onto nitrocel-
lulose membranes. Membrane was blocked with 5% nonfat milk (Lab-
Scientific Inc.) in Tris-buffered saline–Tween buffer. The membranes 
were probed with the antibodies mentioned above.
Site-directed mutagenesis, RT-PCR, and sequencing. Site-directed 
mutagenesis was performed using the QuikChange Lightning Site- 
Directed Mutagenesis Kit (no. 210519, Agilent Technologies). Primers 
for mutagenesis, quantitative real-time PCR (qRT-PCR), and sequenc-
ing were purchased from Life Technologies (Invitrogen). Mutations 
were validated using sanger sequencing.
Annexin staining. Annexin V staining was performed using annex-
in V–conjugate Alexa Fluor 488 (Invitrogen, Life Technologies) and 
annexin-binding buffer (no. V13246, Invitrogen, Life Technologies) 
according to the manufacturer’s protocol. For cell-cycle analysis, cells 
were stained with propidium iodide (Roche) to ascertain the DNA con-
tent and determine cell-cycle distribution within the cell population 
(39). Each experiment was performed in triplicate.
Clonogenic assay. For clonogenicity (colony formation) assay, cells 
were plated at a low density in 6-well plates. After 24 hours, cells were 
treated with SMAPs and incubated for 3 weeks. Cells were then fixed 
and stained with 1% crystal violet (Sigma-Aldrich) solution. Quanti-
fication was performed through the cell counter function on ImageJ 
(NIH). Each experiment was plated and repeated in triplicate.
Mouse models and treatment studies. KrasLA2 mice were purchased 
from the National Cancer Institute Mouse Repository. For xenograft 
studies, H358 (1 × 107), A549 (5 × 106), and H441 (5 × 106) cells were 
injected into the right flanks of 6- to 8-week-old male BALB/c nu/nu 
mice (Charles River Laboratories). For PDX studies, KRAS mutant PDX 
tumor models were purchased from the Jackson Laboratory (model 
TM00231). Tumor fragments were surgically reimplanted in the right 
flanks of NSG mice. When tumor volumes reached an average of 200 
mm3, mice were randomized to treatment groups and tumor volume 
was assessed by caliper measurement every other day throughout the 
study. Mice were treated by gavage with vehicle control, MK2206 (6 
mg/kg), AZD6244 (24 mg/kg), SMAP (5 mg/kg or 15 mg/kg), and 
SMAP2 (100 mg/kg). Mouse body weights were recorded weekly, and 
percentages of mouse body weights during treatment were calculat-
ed as follows: weight at each time point/initial weight × 100. Animals 
were observed for signs of toxicity (mucous diarrhea, abdominal stiff-
ness, and weight loss). Blood and tumor tissue were harvested 2 hours 
after the final dose of the treatment study. Animals were submitted for 
toxicology testing at IDEXX Laboratories. Tumors were both formalin 
fixed, for IHC, and snap-frozen in liquid nitrogen, for immunoblotting.
TUNEL assay and immunohistochemistry. Tissue was fixed in 10% 
buffered formalin phosphate (Fisher Scientific, no. SF100-4), trans-
ferred to 70% ethanol, and blocked in paraffin. Serial tissue sections 
(5-μm thick) were cut from the paraffin-embedded blocks and placed 
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final PP2A AC protein concentration was adjusted to 1 μg/μl. For HRF 
experiments, the purified material was buffer exchanged 2 times with 
20 volumes excess of 1× PBS, pH 7.4 (1.1 mM potassium phosphate 
monobasic, 155.2 mM sodium chloride, 3.0 mM sodium phosphate 
dibasic, Invitrogen) using a 0.5 ml 10K MWCO filter (Millipore). The 
PP2A AC-DT complexes for HRF were made by adding various SMAP 
compounds to PP2A AC at a protein/drug molar ratio of 1:10. For all 
experiments with and without SMAP compounds, the final PP2A AC 
protein concentration was adjusted to 3 μM.
PAL and PP2A proteolysis. PP2A AC protein (1 μg/ μl; 20 μl volume) 
was exposed to a 350 nm (e.g., long wavelength) UV light source for 15 
minutes in the presence of SMAP DT-453 drug at a protein/drug molar 
ratio of 1:20 and in the absence of DT-453 (positive control). In addi-
tion, 20 μl of PP2A AC protein without DT-453 was prepared without 
any UV light exposure (negative control). Subsequently, the DT-453–
PP2A complex and the positive and negative controls were reduced 
with 20 mM DTT at 37oC for 1 hour and alkylated with 50 mM iodoac-
etamide at room temperature in the dark for 30 minutes. PAL samples 
were digested using modified trypsin (Promega) at an enzyme/protein 
molar ratio of 1:10 at 37oC overnight. PAL experiments were attempt-
ed 3× with the same protein preparation.
Synchrotron radiolysis and protein proteolysis. Radiolysis experi-
ments were performed at beamline X28X of the National Synchrotron 
Light Source (Brookhaven National Laboratory, Upton, New York, 
USA) and at beamline 5.3.1 of the Advanced Light Source (Lawrence 
Berkeley National Laboratory, Berkeley, California, USA). The x-ray 
beam parameters were optimized by using Alexa Fluor 488 fluoro-
phore assay (41). All samples were exposed for 0 to 20 milliseconds 
(X28X) and for 0 to 800 μs (5.3.1) at ambient temperature and imme-
diately quenched with methionine amide at a 10 mM final concentra-
tion to prevent secondary oxidation (42). Prior to the PP2A AC prote-
olysis, all protein samples were reduced with 10 mM DTT at 56oC for 
45 minutes and alkylated with 25 mM at room temperature in the dark 
for 45 minutes. For pepsin digestion, formic acid (FA) was added to the 
radiolyzed samples at a final concentration of 0.5% to adjust the pH of 
the samples to around 2. For trypsin digestion, the pH of radiolyzed 
samples was adjusted to 8.0 using 1 M Tris, pH 8.5. Samples then were 
digested with pepsin and trypsin (Promega) at 37oC for 3 hours and 
overnight, respectively, at an enzyme/protein molar ratio of 1:10. The 
digestion reactions were terminated by freezing the samples.
LC-MS analysis. LC-MS experiments were carried out on an 
Orbitrap Elite Mass Spectrometer (Thermo Electron) interfaced with a 
Waters nanoAcquity UPLC System. Peptic peptides were desalted on a 
trap column (180 μm × 20 mm packed with C18 symmetry, 5 μm, 100 
Å; Waters) and subsequently resolved on a reversed phase column (75 
μm × 250 mm nano column, packed with C18 BEH130, 1.7 μm, 130 Å, 
Waters) using a gradient of 2% to 45% mobile phase B (0.1% FA and 
acetonitrile [ACN]) and mobile phase A (100% water/0.1 % FA) over a 
period of 60 minutes at 37 °C and a flow rate of 300 nl/min. A total of 
2 pmol of digested peptides was loaded on the column. Peptides elut-
ing from the column were introduced into the nanoelectrospray source 
with a capillary voltage of 2.5 kV. For MS analysis, a full scan was record-
ed for eluted peptides (m/z range of 360–1600) in the FT mass analyz-
er at resolution R of 120,000, followed by MS2 of the 20 most intense 
peptide ion scans in the ion trap (IT) mass analyzer. All MS data were 
acquired in the positive ion mode. Detected ion currents for peptides 
in MS1 experiments were used to determine the extent of oxidation for 
on charged glass slides. Tumor sections were stained with H&E and 
p-ERK (no. 4370, Cell Signaling Technology). Briefly, sections were 
deparaffinized with xylene and rehydrated through graded alcohol 
washes, followed by antigen retrieval in a pressure cooker (Dako) in 
citrate buffer (10 mM, pH 6.0, Vector Laboratories). Slides were then 
incubated in hydrogen peroxide–methanol, followed by incubation 
in normal goat serum in PBS. Antibody was applied overnight at 4°C. 
DAB substrate was applied, followed by counterstaining in hematox-
ylin. The ApopTag Fluorescein In Situ Apoptosis Detection Kit (Mil-
lipore) was used according to the manufacturer’s protocol to perform 
the TUNEL assay. Prior to the addition of TdT enzyme, sections were 
deparaffinized with xylene and rehydrated through graded alcohol 
washes. VECTASHIELD Mounting Medium with Propidium Iodide 
(Vector Laboratories) was used for counterstaining. Bright-field and 
fluorescent images were captured using an Olympus MVX10 or Zeiss 
Axioplan 2 IE microscope. Quantification was completed using the 
cell counter function of ImageJ (NIH). Imaging was performed at the 
Microscopy CORE at the Icahn School of Medicine at Mount Sinai.
PP2A-binding assay. For the equilibrium dialysis binding studies, 
the RED system (ThermoFisher) was used. Purified protein and radiola-
beled compound were incubated using the RED device for 6 to 8 hours or 
overnight, and drug binding was determined by measuring radioactivity 
by liquid scintillation counting. The percentage of bound drug was calcu-
lated by the following equation: % free = (concentration buffer chamber/
concentration protein chamber) × 100 % bound = 100% – % free.
Phosphatase activity assay using DiFMU. Assay buffer was 50 mM 
MOPS, pH 7.5, 100 mM NaCl, 0.1% 2-ME, 10 mM MgSO4, and 1 mM 
MnCl2. 6,8-Difluoro-4-methylumbelliferyl phosphate (DiFMUP, Invi-
trogen D6567) was added to a final concentration at 100 μM to 1 nM 
PP2A AC dimer (WT and mutants). Samples were incubated at 25°C, 
and activity was measured from fluorescence measured at 358/455 
nm with plate reader.
Assays of PP2A with ProFluor Ser/Thr peptide substrate. PP2A AC 
dimer and recombinant AB56C trimer assembled from purified 
recombinant subunits were assayed for phosphatase activity using 
the ProFluor Ser/Thr R110 Substrate System (Promega) following the 
manufacturer’s instructions. The PP2A were assayed over a range of 
0 to 100 ng to demonstrate a linear response range, and 15 ng of AC 
and 10 ng AB56C were used to test for effects of compounds that were 
included at the indicated final concentrations (0.1 to 20 μM). Activities 
are plotted as the percentage relative to control with no added com-
pound, set as 100%. TRC-766 is an inactive compound. Assays were 
completed in triplicate with calculation of the mean and SEM, shown 
by the error bars.
Modeling of interactions between SMAP and PP2A. Crystal structure 
for PP2A was retrieved from PDB (PDB ID: 2IAE), and the coordinates 
for SMAP were sketched using PubChem (https://pubchem.ncbi.nlm.
nih.gov/). Structures of PP2A and SMAP were prepared for docking 
using the Protein Preparation Wizard and LigPrep module from the 
Schrödinger package (Schrödinger, LLC). Glide XP (extra precision) 
was used to dock SMAP into the region spanning HEAT domains 5–10 
within the A subunit of PP2A. Docking results were visually analyzed 
using PyMol (https://www.pymol.org/).
PP2A AC protein preparation. The AC form of the PP2A was puri-
fied as described by Xu et al. (40). For PAL experiments, PP2A AC 
was buffer exchanged 2 times with 20 volumes excess 25 mM Tris, 
50 mM sodium chloride, and 5 mM dithiothreitol (DTT), pH 7.8. The 
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Study approval. All animal experiments were approved by the 
IACUCs at Icahn School of Medicine at Mount Sinai and Case West-
ern Reserve University. Animal use and care were in strict compliance 
with institutional guidelines, and all experiments conformed to the 
relevant regulatory standards established by Icahn School of Medicine 
at Mount Sinai and Case Western Reserve University.
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each modified site by separate quantification of the unmodified pro-
teolytic peptides and their radiolytic products. The resulting MS2 data 
were initially searched against a PP2A AC protein database using Mass 
Matrix software to identify all specific sites of modification (43). In par-
ticular, MS2 spectra were searched for nonspecific peptides of PP2A 
using mass accuracy values of 8 ppm and 0.7 daltons for MS1 and MS2 
scans, respectively, with the allowed variable modifications, including 
carbamidomethylation for cysteines and all known oxidative modifica-
tions for amino acid side chains (44, 45). In addition, all detected MS2 
spectra for each site of modification were manually verified.
Modification rate calculation. The integrated peak areas of the 
unmodified peptide (Au), and of a peptide in which a residue is mod-
ified (Am) derived from selected ion chromatograms, were used to cal-
culate the fraction unmodified (Fu) for each specific modified species 
according to the following formula: Fu = 1 – (Am/(Au + SAm)), where ΣAm 
is the sum of all modified products for a particular peptide. Dose-re-
sponse curves were generated using unmodified fractions for each spe-
cific site of modification plotted versus x-ray exposure time. The frac-
tion unmodified for each site of modification was fit to the following 
first-order equation: Fu = (Fu)0e-kt, where Fu and (Fu)0 are the fractions 
of unmodified values at each site of modification at time t and time 0 
(seconds), respectively, and k is a first order rate constant as previously 
described (46, 47). Dose-response curves were presented as unmodi-
fied fractions for each specific site of modification plotted versus x-ray 
exposure time. The modification rates were obtained from the slope of 
the dose-response curves. The protection factors (PFs) were calculated 
by dividing the modification rates for each modified site derived from 
the drug-free PP2A AC protein by the modification rates for the same 
sites of modification derived from the PP2A AC protein bound to the 
various SMAP compounds. The peptide segments and the amino acid 
side chains in each segment for which PFs were determined are pro-
vided as supplementary information (Supplemental Table 4).
Statistics. Enhanced chemiluminescent images of immunoblots 
were analyzed by scanning densitometry and quantified with ImageJ 
(NIH) software. All values were normalized to GAPDH expression and 
expressed as fold change relative to control. Analysis was performed 
using GraphPad Prism. Statistical significance was assumed for a 
2-tailed P value of less than 0.05 using Student’s t test or ANOVA with 
Tukey’s post-hoc test (presented as means; error bars indicate SD). 
Except where otherwise noted, box boundaries of all box-and-whis-
ker plots represent the range of values obtained in the experiment and 
whiskers represent mean ± SD.
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